Mostra i principali dati dell'item
Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NFκB Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression
dc.creator | Mitrakas L., Gravas S., Papandreou C., Koukoulis G., Karasavvidou F., Dimakopoulos G., Weingärtner K., Karatzas A., Zachos I., Tzortzis V. | en |
dc.date.accessioned | 2023-01-31T09:00:28Z | |
dc.date.available | 2023-01-31T09:00:28Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.1007/s12253-017-0340-1 | |
dc.identifier.issn | 12194956 | |
dc.identifier.uri | http://hdl.handle.net/11615/76669 | |
dc.description.abstract | To investigate the potential prognostic role of NFκB expression in primary high-grade non-muscle-invasive bladder cancer. Patients with primary high-grade non-muscle-invasive bladder cancer who received induction and maintenance BCG therapy were retrospectively included. Recurrence and progression were histologically proven. Intensity and extent of immunochemistry were assessed. The final evaluation of the NFκB staining was done by combining intensity and extent as ΄΄product΄΄ and expressing it as ΄΄low NFκΒ expression΄΄ or ΄΄high NFκB expression΄΄. Epidemiological, pathological, clinical parameters and NFκB expression were statistically analyzed for recurrence (REC), progression (PR), recurrence-free survival (RFS) and progression-free survival (PFS). NFκB is significantly associated with disease progression (p < 0,001 in univariate analysis and p = 0,001, Odds Ratio = 14,484, 95% Confidence Interval = 3187-65,821 in multivariate analysis), but not with recurrence. The median value of NFκB expression as ΄΄product΄΄ is significantly higher for the patients with progression in comparison to patients with recurrence only (p = 0,003) and patients without recurrence or progression (p = 0,001). Patients’ age is significantly associated (p = 0,001 in univariate analysis and p = 0,003, Odds Ratio = 1273, 95% Confidence Interval = 1086–1492 in multivariate analysis) with disease recurrence. High NFκB expression in primary high-grade non-muscle-invasive bladder cancer, treated with postoperative intravesical BCG immunotherapy, could represent an unfavorable prognostic factor. © 2017, Arányi Lajos Foundation. | en |
dc.language.iso | en | en |
dc.source | Pathology and Oncology Research | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032370942&doi=10.1007%2fs12253-017-0340-1&partnerID=40&md5=65d49aa8c0137e53a418dd6f128dd904 | |
dc.subject | BCG vaccine | en |
dc.subject | epirubicin | en |
dc.subject | immunoglobulin enhancer binding protein | en |
dc.subject | immunoglobulin enhancer binding protein | en |
dc.subject | tumor marker | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | bladder carcinogenesis | en |
dc.subject | cancer grading | en |
dc.subject | cancer growth | en |
dc.subject | cancer immunotherapy | en |
dc.subject | cancer prognosis | en |
dc.subject | cancer recurrence | en |
dc.subject | cancer risk | en |
dc.subject | cancer staging | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | human | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | non muscle invasive bladder cancer | en |
dc.subject | postoperative period | en |
dc.subject | progression free survival | en |
dc.subject | protein expression | en |
dc.subject | protein function | en |
dc.subject | recurrence free survival | en |
dc.subject | retrospective study | en |
dc.subject | transurethral resection | en |
dc.subject | bladder tumor | en |
dc.subject | cancer grading | en |
dc.subject | disease exacerbation | en |
dc.subject | immunotherapy | en |
dc.subject | metabolism | en |
dc.subject | middle aged | en |
dc.subject | pathology | en |
dc.subject | survival rate | en |
dc.subject | tumor invasion | en |
dc.subject | tumor recurrence | en |
dc.subject | very elderly | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Biomarkers, Tumor | en |
dc.subject | Disease Progression | en |
dc.subject | Female | en |
dc.subject | Follow-Up Studies | en |
dc.subject | Humans | en |
dc.subject | Immunotherapy | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Grading | en |
dc.subject | Neoplasm Invasiveness | en |
dc.subject | Neoplasm Recurrence, Local | en |
dc.subject | NF-kappa B | en |
dc.subject | Retrospective Studies | en |
dc.subject | Survival Rate | en |
dc.subject | Urinary Bladder Neoplasms | en |
dc.subject | Springer Netherlands | en |
dc.title | Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NFκB Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |